1-4 of 4
Yan Nikhamin, MS
Close
Sort by
Journal Articles

Constitutive Expression of CD40L by CAR-Modified Tumor Targeted T Cells Enhances Anti-Tumor Efficacy Both in Vitro and in Vivo

Kevin J. Curran, MD, Beatrijs Seinstra, MD, Yan Nikhamin, MS, MBA, Raymond Yeh, PhD, Yelena Usachenko, BS, Renier J Brentjens, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4120.
https://doi.org/10.1182/blood.V120.21.4120.4120
Published: 2012
Journal Articles

Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia

James J. Harding, MD, Raymond Yeh, PhD, Yan Nikhamin, MS, MBA, Mark Frattini, MD, Nicole Lamanna, MD, Joseph G Jurcic, MD, Mark Heaney, MD, PhD, Renier Brentjens, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3595.
https://doi.org/10.1182/blood.V116.21.3595.3595
Published: 2010
Journal Articles

Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy.

James Lee, BA, Yan Nikhamin, MS, Gavin Imperato, MS, Adam Cohen, MD, Michel Sadelain, MD/PhD, Renier Brentjens, MD/PhD
Journal: Blood
Blood (2007) 110 (11): 2754.
https://doi.org/10.1182/blood.V110.11.2754.2754
Published: 2007
Journal Articles

Sensitive In Vivo Detection of Primary T Cells Expressing Membrane-Anchored Gaussia Luciferase for the Study of Adoptive T Cell Immunotherapy in Murine Models of Malignancy.

Renier J. Brentjens, MD, PhD, Elmer Santos, MD PhD, Raymond Yeh, PhD, Krista La Perle, DVM, Ricardo Toledo-Crow, PhD, Yan Nikhamin, MS, Blesida Punzalan, BS, David Entenberg, BS, Iana Aranda, BS, Bleserene Punzalan, BS, Steven Larson, MD, Michel Sadelain, MD PhD
Journal: Blood
Blood (2006) 108 (11): 3685.
https://doi.org/10.1182/blood.V108.11.3685.3685
Published: 2006